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INTRODUCTION: Incisionalbiopsies, including thediagnostic coreneedlebiopsy (CNB), routinelyperformedbefore surgical
excision of breast cancer tumors are hypothesized to increase the risk ofmetastatic disease. In this study,weexperimentally
determinedwhether CNB of breast cancer tumors results in increased distant metastases and examine important resultant
changes in the primary tumor and tumormicroenvironment associatedwith this outcome.METHOD: To evaluate the effect
ofCNBonmetastasisdevelopment,we implantedmurinemammary4T1 tumor cells inBALB/cmiceandperformedCNBon
palpable tumors in half themice. Subsequently, emulating thehumanscenario, allmiceunderwent complete tumor excision
andwere allowed to recover, with attendantmetastasis development. Tumor growth, lungmetastasis, circulating tumor cell
(CTC) levels, variation in gene expression, composition of the tumor microenvironment, and changes in immunologic
markers were compared in biopsied and non-biopsied mice. RESULTS:Mice with biopsied tumors developed significantly
more lung metastases compared to non-biopsied mice. Tumors from biopsied mice contained a higher frequency of
myeloid-derived suppressor cells (MDSCs) accompanied by reduced CD4+ T cells, CD8+ T cells, and macrophages,
suggesting biopsy-mediated development of an increasingly immunosuppressive tumor microenvironment. We also
observed a CNB-dependent up-regulation in the expression of SOX4, Ezh2, and other key epithelial-mesenchymal transition
(EMT) genes, aswell as increasedCTC levels among the biopsy group.CONCLUSION:CNBcreates an immunosuppressive
tumor microenvironment, increases EMT, and facilitates release of CTCs, all of which likely contribute to the observed
increase in development of distant metastases.
Neoplasia (2014) 16, 950–9602The authors thank the Canadian Breast Cancer Foundation, the Beatrice Hunter
Cancer Research Institute, the Dalhousie University Senior Clinical Scholar Award, and
Dalhousie Medical Research Foundation Adopt-a-Researcher Program for their
financial support that made this study possible.
Received 18 July 2014; Revised 10 September 2014; Accepted 16 September 2014
© 2014 Neoplasia Press, Inc. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1476-5586/14
http://dx.doi.org/10.1016/j.neo.2014.09.004
Neoplasia Vol. 16, No. 11, 2014 Core Needle Biopsy of Breast Cancer Tumors Mathenge et al. 951Introduction immune-competent, cancer animal model considered to closelyBreast cancer is themost common cancer affecting women and accounts
for the second highest incidence of cancer-related death, after lung
cancer [1]. There are numerous factors known to influence the
metastatic potential of any given breast cancer (tumor size, receptor
status, lymph node involvement at the time of diagnosis, age of the
patient, menopausal status, and family history) [2–5]. However, the
most consistent predictors of metastasis continue to be tumor size and
lymph node involvement at the time of diagnosis [6,7]. Because of this,
breast cancer screening and early detection are critically important in
improving outcomes for women with breast cancer.
Suspicious lesions detected on screening mammograms are
generally biopsied to confirm or rule out a diagnosis of cancer. The
most common form of biopsy administered today is a core needle
biopsy (CNB) [8–14]. A CNB is a form of incisional biopsy whereby
a portion of a tumor is removed for histologic evaluation leaving the
remainder in vivo to be removed at a later date following a definitive
diagnosis. Typically with breast cancer, tissue samples are collected by
administering three to nine passes with a 14G biopsy needle [15,16].
Biopsy needle sizes can range from 9G to 18G depending on the
particular form of image guidance and system of sample acquisition
used for the core biopsy [17–19].
Other breast cancer biopsy techniques include complete excisional
biopsy, open incisional biopsy, and fine needle aspiration. CNB and
fine needle aspiration are favored over open incisional or excisional
biopsies because they are less invasive, produce a smaller cosmetic
post-operative footprint, and result in faster patient recovery. This is
particularly appealing given that the majority of biopsied breast
lesions are ultimately ruled benign [20,21]. Furthermore, in
addition to distinguishing invasive from non-invasive cancer, tissue
obtained from CNB can be used to perform nucleic acid analysis,
immunohistochemistry, or analysis of prognostic biomarkers [22–24].
As a consequence, stereotactic or ultrasonographically guided CNB is
currently the predominant biopsy method employed in breast cancer
management [16].
Incisional surgical procedures, including incisional biopsies, on
cancers have historically been associated with higher local recurrence
rates and elevated incidence of lymph node metastasis [25–29]. There
is also a growing body of evidence suggesting that surgical trauma in
the presence of an established neoplasm can potentiate its growth and
metastatic proliferation [30–33].
Current literature also increasingly notes the occurrence of post-
surgical immunosuppressive changes and their relevance to metastatic
spread and disease recurrence [33]. These observations suggest that
surgically instigated changes in the tumor and subsequent host interaction
with residual disease can influence the tumor’s metastatic potential.
The clinical impact and potential risk associated with performing a
CNB has long been debated. There is compelling evidence that CNB
increases the risk of needle track seeding and local tumor recurrence in
patients with breast cancer [28,34,35]. There is also little question that
cancer cells from both invasive and non-invasive breast cancers enter
lymphatic channels and migrate to lymph nodes following a biopsy
procedure [27,36]. However, whether or not cancer cells displaced into
lymphatic and vascular channels are capable of effectively establishing
distant metastases remains unproven [34,37–39].
To test the hypothesis that surgically initiated changes in the
tumor microenvironment due to CNB results in increased metastatic
spread, we used the 4T1-BALB/c mouse model, a well-established,mimic metastatic breast cancer in humans. Murine mammary 4T1
tumor cells were orthotopically implanted in BALB/c mice and
tumors large enough to biopsy developed within 2 to 3 weeks.
Biopsies were then performed in a manner designed to experimen-
tally replicate the human clinical experience of using CNB for the
diagnostic workup of breast cancer as well as study the impact of the
CNB on metastatic outcomes. In this model, tumors spontaneously
metastasize from the mammary fat pad to lymph nodes, lung, and
bone in a similar pattern to that observed in human breast cancers
[40]. This immunologically intact model also enabled study of the
immunologic changes associated with CNB within the local tumor
microenvironment, in distant organs, and peripheral circulation.
These changes were assessed to detect those events that might be
associated with tumor progression and metastasis [41]. Gene
expression profiles were evaluated to detect changes in known key
epithelial-mesenchymal transition (EMT) genes [42]. Recent studies
have drawn associations between surgical procedures and increased
levels of tumor cells in circulation [43]. In consideration of this
finding, and the documented link between circulating tumor cell
(CTC) levels and metastasis [44,45], the impact of CNB on CTC
levels was also measured.
Methods
Cells
Metastaticmurine breast cancer cell line 4T1 (ATCCCRL-2539) cells
were cultured in RPMI-1640, supplemented with 10% FBS and
antibiotic-antimycotic, at 37°C at 90% humidity and 5% CO2. All
media, sera, and supplements used for the murine metastasis model were
purchased from Invitrogen, Life Technologies (Burlington, Ontario).
Animals
Female BALB/c mice were obtained from Charles River Laboratory
(St-Constant, Canada) and housed in the Carleton Animal Care
Facility at Dalhousie University. After a 1 week acclimatization
period, the mice were used in the study. All protocols (No. 09-044
and No. 13-088) were approved by the Dalhousie University
Committee on Laboratory Animals in keeping with guidelines
established by the Canadian Council on Animal Care (CCAC).
Metastasis Model
Mice received a subcutaneous orthotopic injection of 7 × 103 4T1
tumor cells into the third thoracic mammary fat pad. Primary tumors
were palpable in 10 to 16 days and reached the biopsy size of 6 to
8 mm by 15 to 20 days after implantation. Mice with slow-growing
tumors that failed to achieve the required size for experimentation
were excluded from the study (this was typically no more than 3 mice
from a starting set of 23 mice). Tumor growth was determined by
measuring two axes of the tumor and determining the mean tumor
diameter. At the CNB time point, mice were alternately assigned to
biopsy and non-biopsy groups to eliminate bias. Mice assigned to the
biopsy group were fully anesthetized using inhaled isoflurane (2%
body weight) and their biopsy sites were shaved and subjected to
aseptic surgical preparation; they then received CNB with an 18-
gauge needle attached to a 5-ml syringe. Six to eight cutting passes
were administered in a palmate-radiating pattern through a single
cutaneous insertion point so as to reduce injury to the skin. On
occasion, when a tumor was multilobed or irregularly shaped, an
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distributed through the tumor with the biopsy needle. The non-
biopsy (control) groups received no biopsy but were subjected to an
equal duration of complete anesthesia in a modified induction
chamber. Mice were maintained in a recovery area for 24 hours post
procedure and observed to assure return to normal grooming and
feeding behavior. All mice were monitored regularly throughout the
experiment for any signs of illness or distress and were killed if and
when they became moribund, according to CCAC guidelines.
In the clinical setting, breast cancers are generally biopsied using
image-guided CNB technology to confirm the diagnosis with
definitive (excisional) surgical treatment typically performed 2 or
more weeks following performance of a diagnostic CNB. To
reproduce this process, tumors were excised in both biopsy and
non-biopsy control mice groups 7 days post biopsy/non-biopsy
assignment (Figure 1A). Mice were anesthetized and tumors were
surgically (and aseptically) excised, removing all tumor tissue toB D
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Figure 1. CNB significantly increases lung metastasis. (A) Experime
scenario Detection N Biopsy N Excision NOutcome. Mice were implan
the mice are alternately assigned to two groups, a biopsied group (n=
excision of the tumors 7 days post biopsy and sacrifice of the mice
biopsy pattern). (B) Tumor growth and (C) body weight were mon
(E) percent metastasis of the lungs were determined by H&E staining
non-biopsy and biopsy mice groups. White pointers indicate lung me
error bars represent the SEM.prevent regrowth. Incisions were sutured shut using Novaril 4. Mice
were given analgesic Ketoprofen (5 mg/kg), monitored regularly for
any signs of illness, and were killed if judged moribund according to
CCAC guidelines.
Excised tumors were divided with a 2 mm × 2 mm × 6 mm sliver of
tissue being snap frozen in TRIzol and RNAlater (Qiagen GmbH,
Hilden, Germany) for later RNA extraction and quantitative
polymerase chain reaction (qPCR) gene expression analysis, as
described in the Quantification of Gene Expression by qPCR section.
The remaining tumor tissue was placed in 10% formalin buffered
with sodium acetate for paraffin embedding and histologic analysis.
Histologic Quantification of Pulmonary Metastasis and
Tumor Necrosis
To compare the level of metastasis and associated necrosis between
biopsied and non-biopsied mice, a total of 84 mice in four cohorts
underwent the metastasis model described above. Cohort size wasiopsy Biopsy
ns
iopsy Biopsy
*
 Biopsy Excision Surgery (Day 7 p.b.) Sacrifice (Day 14 p.b.)
Ø ≥ 6∼ mm Organs  collected for 
                              Histological analysis
Non-Biopsy
Biopsy
F 
nt schematic mimicking the format of progression in the human
ted with 4T1 cells, and after 6- to 8-mm diameter tumors developed,
40), and a non-biopsy group (n= 44). This was followed by surgical
at 14 days post biopsy (circular inset: details radiating a palamate
itored post biopsy. (D) Percent necrosis of excised tumors and
of fixed tissue sections. (F) Representative section of lungs from
tastases. Significance determined by an unpaired t test, *P ≤ .05;
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treatment and surgical handling. Seven days after the tumor excision,
each cohort of mice consisting, on average, of biopsy (n = 10) and non-
biopsy (n = 11) mice was sacrificed. The draining lymph nodes and lungs
were harvested, formalin fixed, and paraffin embedded with each block
assigned an anonymizing numerical identifier to allow unbiased
evaluation. The anonymized lungs, lymph nodes, and tumors were serial
sectioned into 5-μm thin tissue sections and stained with hematoxylin
and eosin (H&E) for histologic evaluation. Imaging was performed using
a Zeiss AxiocamHRCColor, mounted on a Zeiss Stemi. The percentage
of metastatic (lung and lymph node) and necrotic (tumor) tissue areas
relative to total section area was established using an overlay grid imposed
on images captured from H&E-stained tissue sections.
Quantification of CTCs in Peripheral Circulation post Biopsy
Using 4T1neo Cells
To quantify CTCs in circulation, we generated neomycin cassette-
bearing 4T1 cells using the Clontech retroviral expression system
(Clontech Laboratories, Mountain View, CA; Cat. No. 634401). The
cells were selected for stable expression of the neomycin resistance gene by
multiple passages under RPMI-1640 with 100 μg/ml G418 sulfate
(Fisher Scientific Co., Fair Lawn, NJ), and the resulting cells were
designated 4T1neo cells.
To assess changes in the level of CTCs, the 4T1neo cells were
implanted in the mammary fat pad of a single group of 12 BALB/c
mice using a procedure identical to that used for unmodified 4T1
cells. The mice developed similar sized tumors in the same time frame
as unmodified 4T1 implanted mice. The 12 mice implanted with
4T1neo cells were biopsied when the 6- to 8-mm tumor diameter
threshold was achieved. Groups of mice (n = 4) were processed for
each post-biopsy time point (6 hours, 24 hours, and 10 days). Mice
were bled through facial vein with 200 μl of blood collected and
immediately mixed with 1 ml of TRIzol reagent. This was snap frozen
in liquid nitrogen and stored at −80°C until RNA was extracted and
qPCR was performed for neomycin gene expression. Mice were
sacrificed, and their tumors harvested and processed in RNAlater for
subsequent RNA extraction and gene expression analysis by qPCR.
Quantification of Gene Expression by qPCR
Immediately after blood collection for analysis, mice from biopsy (n = 5)
and non-biopsy (n = 5) groups were sacrificed for the 0-, 3-, 12-, and 24-
hour post biopsy time points (n = 40). Sections of tumor and lung were
harvested and snap frozen in TRIzol and RNAlater (Qiagen Inc). Frozen
tissue samples were later thawed, the tissue was crushed, and the RNA
extracted using Purelink RNA Kit (Invitrogen Inc). Generation of cDNA
was performed using Superscript II (Invitrogen Inc). For qPCR analysis of
relative expression of genes of interest, specific primers for neomycin
resistance gene (Neo), S100A8, Ly-6G (Gr-1), CXCL2 (MIP-2), CCL3
(MIP-1a), FOXP3, transforming growth factor–β (TGF-β), SOX-4,
Ezh2, SNAI2, ZEB2, CDH2 (N cadherin), Interleukin-1 beta (IL-1β),
IL-10, Tumor Necrotic Factor-alpha (TNF-α), matrix metalloproteinase
9, and urokinase plasminogen activator were designed on the basis of
RefSeq data for Mus musculus using the NCBI Primer-BLAST online
primer designing tool (Table S1).
Using the Bio-Rad CFX-96 system, qPCR assay was performed
and analysis of results was done using the CFX manager software
applying ΔΔCt analysis with relative normalization calculations based
on the murine glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and β-actin housekeeping genes.Flow Cytometry
To study variation in immune cellular populations in the tumor and
lung microenvironments and systemic immune changes related to
performance of a CNB, a single cohort of 60mice was used. Twentymice
from the biopsy (n = 10) and non-biopsy (n = 10) groups were sacrificed
on each assigned post-biopsy time point (days 3, 7, and 10). Sections of
tissue from tumor, lung, spleen, and lymph node were harvested and
immediately processed and labeled with CD4− fluorescein isothiocya-
nate, CD3− Phycoerythrin (PE), CD8−PerCP,Dx5 (Pan-Natural Killer
[NK])− APC, CD45− fluorescein isothiocyanate, Ly6G (Gr-1)–PE,
CD11b-PerCP, and F4/80-APC antibodies (eBioscience Inc., SanDiego,
CA) allowing quantification of CD4+ T cells, CD8+ T cells, NK cells,
macrophages, and myeloid-derived suppressor cells (MDSCs). Using a
FACScalibur flow cytometer (BD Biosciences, CA), data were collected
and analyzed using CellQuest Pro (BD Biosciences), FCS express ver. 4
(DeNovo Software, CA), and Flowing Software ver. 2.5 (University of
Turku, Turku, Finland).
Statistical Analysis
Statistical significance was established relative to baseline values at
0 hour post biopsy or values recorded for non-biopsied samples and
determined using non-parametric two-tailed t test performed on
GraphPad Prism software. For all analyses, a P value greater than .05
was considered not significant, while significant P values were
demarcated using the standard increasing asterisk scale to indicate
level of significance, *P ≤ .05, **P ≤ .01, and ***P ≤ .001.
Results
CNB Is Associated with Significantly Increased
Pulmonary Metastases
To investigate whether CNB has an effect on the development of
pulmonary metastasis, we first implanted the mammary fat pads of
BALB/c mice with 4T1 murine breast cancer cells. Tumors were
allowed to grow to 6- to 8-mm diameter at which point CNB was
performed in half the mice and the tumor growth rate was quantified
in all mice for the following week (Figure 1A). Our results illustrate
that tumor growth rates were not significantly affected by CNB
(Figure 1B). There was also no significant difference between the
body weights of the biopsied and non-biopsied groups (Figure 1C).
Next, to reproduce the human experience, we surgically removed the
tumors from all themice (biopsied and non-biopsied) and themicewere
allowed to recover. Histologic comparison of excised tumors from
biopsied mice versus those from non-biopsied mice showed similar
levels of necrosis (Figure 1D). One week following surgical excision of
their tumors, all mice were sacrificed and the lungs were analyzed for
metastasis. Mice that had undergone CNB demonstrated significantly
greater lungmetastasis (Figure 1,E and F). Importantly, this suggests that
CNB performed before surgical excision of a tumor may unintentionally
promote metastatic dissemination.
CNBs Create an Immunosuppressive Tumor Microenvironment
It is well established that an immunosuppressive tumor
microenvironment facilitates malignant progression by promoting
tumor immune evasion, angiogenesis, and metastasis [46–48].
Furthermore, surgical procedures are known to induce suppressive
immune conditions including infiltration by immune cells with
suppressive capacities such as MDSCs [46,49]. Therefore, following
the regimen illustrated in Figure 2A, we investigated whether the
increased metastasis observed in mice after CNB is also associated
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Figure 2. CNBs induce an immunosuppressive tumor microenvironment. (A) Mice were implanted with 4T1 cells, and after 6- to 8-mm
diameter tumors developed, half the mice were biopsied (n= 30), while the other half were not biopsied (n= 30). The tumor, spleen, and
lungs were collected from 10mice from each group for flow cytometry analysis of the indicated immune cells at 3, 7, and 10 days after the
biopsy date. NK cells were only monitored on days 3 and 7 post-biopsy date. Significance determined by unpaired t test, *P ≤ .05; error
bars represent SEM.
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vironment. Flow cytometry was used to quantify macrophages
(CD45+, CD11blow, F4/80+), MDSCs (CD45+, CD11b+, Gr-1+),CD4+ T cells, CD8+ T cells, and NK cells (Pan-NK, CD3+)
(Figure S1A). Data were collected on the frequencies of these cells in
the primary tumor, spleen, lymph node, and lungs. It was found that
Neoplasia Vol. 16, No. 11, 2014 Core Needle Biopsy of Breast Cancer Tumors Mathenge et al. 955on day 3 post biopsy there was a significant increase in the frequencies
of MDSCs with a concurrent decrease in macrophage, CD4+ T cell,
and CD8+ T cell frequencies in the tumors of mice from the biopsy
group compared to non-biopsied controls. On day 7,CD4+ andCD8+
T cell and macrophage levels were significantly higher in lung tissue
from the biopsy group compared to non-biopsy controls (Figure 2B).
Additionally, during the post-biopsy period, there was a gradual
decrease in the frequencies of MDSCs, CD4+, and CD8+ T cells and
an increase in macrophages in the spleen in both groups. Furthermore,
monitoring the frequencies of the NK cells during the first 7 days
post biopsy revealed that there were higher frequencies of these
innate immune cells in the lung tissue from the biopsy group on day
7 post biopsy compared to non-biopsied controls (Figure 2B).
Although trends were observed in the spleen (Figure 2B) and lymph
nodes (Figure S1B), both showed no significant difference in recorded
immune cell frequencies when comparing biopsy and non-biopsy
groups over 10 days post CNB.
Together, our data demonstrate that the CNB procedure
impacts the level of immune cells at both local and systemic sites
and promotes the development of an immunosuppressive
immune milieu in the local tumor microenvironment immedi-
ately following CNB.
CNB Alters the Expression of Cytokines in the Local Tumor
Microenvironment
The recruitment, pathophysiology, and functionality of immune
cells are dictated by various soluble mediators (cytokines and
chemokines) [50]. Hence, we next investigated whether CNB altered
the expression of various pro-inflammatory factors such as S100A8,
CXCL1, CXCL2, IL-1β, TNF-α, and COX2 that can influence the
recruitment and survival of MDSCs, macrophages, and other
immune cells at the tumor site [51–53]. To this end, tumor samples
collected at various time points from biopsied or non-biopsied groups
were processed and analyzed for the expression of a panel of cytokines.
The qPCR analysis of these samples revealed a significant elevation in
the expression of S100A8, CXCL2 (MIP-2α), CCL3(MIP-1α), and
COX2 in tumor tissues as early as 3 hours post biopsy, with this
elevation persisting up to 24 hours post biopsy (Figure 3, A–F).
EMT-Related Changes in Gene Expression Occur within Hours
of a CNB
Activation of the processes of EMT promotes tumor-cell metastasis
through development of dysfunctional cell-cell adhesive interactions,
loss of cell-cell junctions, and restructuring of the cytoskeleton. These
changes, along with the loss of apical polarity, signal the development
of an invasion-permissive, and hence pro-metastatic, microenviron-
ment [54]. To determine if EMT contributes to the changes that
occur post biopsy, we assessed the change in gene expression levels of
known EMT regulators. Our analysis showed that tumor samples
from the biopsied group had significantly increased expression of
TGF-β and SOX-4 compared to that of tumors from the non-biopsied
control group, as early as 3 hours post biopsy (Figure 4A). This was
followed by a significant increase in expression of Ezh2 (amember of the
transcription repressive Polycomb group family) by 24 hours post
biopsy (Figure 4A). Expression of downstream EMT genes SNAI2
(Slug),ZEB2, andCDH2 (N-cadherin) (Figure 4B) was also statistically
significant at 24 hours post biopsy. The timing of TGF-β/SOX-4/Ezh2
expression changes is consistent with involvement of a TGF-β–
initiated, Sox4/Ezh2, EMT pathway. These results suggest that theCNB enhances the expression of genes involved in the development of
EMT within the tumor.
CNB Increases the Number of CTCs
Recent studies have highlighted the prognostic relevance of CTCs
for metastatic breast cancer [55,56]. Reports of generating increased
CTCs as a consequence of incisional biopsies and surgical
manipulation raise concern about increased metastasis as a conse-
quence of biopsy-generated CTCs [43]. We therefore sought to
determine whether CNB affects the level of CTCs in our
experimental model. To accomplish this, we first modified the 4T1
cells to express a neomycin resistance gene (4T1neo cells) that could
be detected sensitively by qPCR. The 4T1neo cells were implanted
and processed as in previous experiments (Figure 2A). At 6 hours,
24 hours, and 10 days post biopsy, blood was collected and the
relative expression of the neomycin resistance gene was quantified as a
measure of the number of 4T1neo cells in peripheral circulation. A
significant elevation in expression of the neomycin resistance gene was
seen in the biopsied group at the 6-hour (P = .008) and 24-hour (P =
.034) time points (Figure 5). These data indicate that the
performance of a biopsy is associated with significantly higher
number of CTCs as early as 6 hours and persisting to beyond
24 hours post biopsy.
Discussion
CNB, a type of incisional biopsy procedure, is commonly performed
in the diagnostic workup of breast cancer. We tested the hypothesis
that surgically initiated changes in the tumor microenvironment
resulting from a CNB and the ensuing host’s interaction with the
residual cancer influence the metastatic potential of that tumor
resulting in increased metastatic spread. Using a 4T1:BALB/c murine
metastatic breast cancer model, we evaluated the impact of
performing a CNB on the following: 1) the development of distant
metastases that occur over and above those expected in this metastatic
model, 2) the status of immune mediators (cells and cytokines) within
the tumor microenvironment, 3) the expression of molecules involved
in EMT, and 4) the number of CTCs.
Our findings demonstrate that CNB performed on malignant breast
cancers significantly increased the incidence of distant metastases above
that which would be expected without biopsy. The observed increase in
metastases is associated with early immunosuppressive changes within
the tumor microenvironment that facilitate metastatic progression.
These changes include recruitment of MDSCs and a concomitant
down-regulation of CD4+ T cells, CD8+ T cells, and NK cells.
Additional findings that support the hypothesis of a CNB-facilitated
metastatic process include the up-regulation early post biopsy of genes
responsible for EMT including involvement of a TGF-β–initiated,
SOX-4/Ezh2, EMT pathway.
Significant decreases in splenic CD4+ T cells and CD8+ T cells,
with associated increase in macrophages, have previously been
recorded in tumor-bearing mice with no biopsy performed
demonstrating that these changes would occur independent of any
biopsy-associated effects [57,58].While these changes in spleen
cellular population are presumed to be a consequence of dynamic
interaction between the tumor microenvironment and the immune
system, the specific mechanism or exact implications of the changes
remain unknown.
In keeping with the cellular changes demonstrated in the post-
biopsy tumor microenvironment, we observed an up-regulation of
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Figure 3. CNB modulates the expression of pro-inflammatory factors within the local tumor microenvironment. Tumor samples collected
from biopsied and non-biopsied mice were processed, and RNA was extracted, purified, and reversed transcribed using random primers.
Real-time qPCR was conducted on the following gene-specific primers: (A) S100A8, (B) CXCL2 (MIP-2α), (C) CCL3(MIP-1α), (D) COX2,
(E) IL-1β, and (F) TNF-α. Gene expression at 0, 3, 12, and 24 hours post biopsy was analyzed using ΔΔCt analysis with relative
normalization with murine GAPDH and β-actin (n= 5; significance is determined relative to levels at 0 hour post biopsy by unpaired t test,
*P ≤ .05; error bars represent SEM).
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CXCL1,CXCL2, IL-1β, TNF-α, andCOX2, which are responsible for
the recruitment of multiple inflammatory and immune cell populations
including neutrophils, macrophages, MDSCs, and Tregs. Increased
S100A8 expression is reportedly associated with chemotactic recruit-
ment of MDSCs as well as the promotion of increased vascular
permeability [49,59]. Increased expression of CCL3 and CXCL2 also
indicate enhanced chemoattraction of granulocytes and MDSCs.
COX2 stimulates production of prostaglandin E2 (PGE2) and has been
reported to increase recruitment of EP2-expressing FoxP3+Tregs to the
tumor through a PGE2/EP2 interaction–dependent pathway [53].
Collectively, this post-biopsy cytokine profile favors a pro-metastatic
tumor microenvironment.
We established that TGF-β expression was significantly increased
post biopsy as was the SOX-4 gene, a master EMT regulator and a
member of the C subgroup of SRY-related HMG box (SOX)
transcription factor family [60]. Further investigation showed
accompanying increases in expression of the epigenetic modifier
Ezh2 as well as increases in the expression of other attendant
downstream EMT genes (ZEB2, SNAI2, and CDH2). These findings
suggest involvement of the TGF-β/SOX-4 EMT pathway, which
would contribute to the increased metastasis we observed through
increased migration and extravasation. Previous studies have shownthat SOX-4 expression is associated with poor metastasis-related
outcomes among early-stage lymph node–negative patients [42,61],
while a separate study correlates SOX-4 expression with triple-negative
breast cancer patients and consequently poor prognosis [60]. In
conjunction with these studies, our findings suggest a mechanistic role
for EMT and relatedmolecules inCNB-induced breast cancermetastasis.
The observed cytokine and EMT-associated gene expression
changes also correlated with significantly elevated CTCs from
biopsied tumor-bearing mice that persisted up to 24 hours post
biopsy. Importantly, other studies have demonstrated that CTC
persistence post-surgery extending to, and beyond, 24 hours is
considered a robust predictor for metastatic recurrence [62]. The
relevance of the CTC/EMT relationship and its role in determining
metastatic outcomes in breast cancer is explored in a recent study by
Yu et al., which highlights the dynamic relationship between EMT
and CTC level and shows the association between cancer subtype,
treatment response, and stage of disease. They reveal that EMT,
and consequently mesenchymal CTCs, occur more prevalently in
aggressive disease subtypes typically characterized as being highly
pro-metastatic [44,63]. The persistent increase in the total CTC
numbers we observed in biopsied mice likely has a cumulative
impact that favors the possibility of successful metastatic
colonization (Figure 6).
0 3 12 24
0
1
2
3
EZH2
*
Time Post Biopsy (Hours)Re
la
tiv
e 
no
rm
al
is
ed
 E
xp
re
ss
io
n
0 3 12 24
0
1
2
3
*
SOX4
*
Time Post Biopsy (Hours)R
el
at
iv
e 
no
rm
al
is
ed
 E
xp
re
ss
io
n
0 3 12 24
0
1
2
3
TGF
*
Time Post Biopsy (Hours)Re
la
tiv
e 
no
rm
al
is
ed
 E
xp
re
ss
io
n
0 3 12 24
0
1
2
3
CDH2
*
Time Post Biopsy (Hours)R
el
at
iv
e 
no
rm
al
is
ed
 E
xp
re
ss
io
n
0 3 12 24
0
1
2
3
ZEB2
*
*
Time Post Biopsy (Hours)R
el
at
iv
e 
no
rm
al
is
ed
 E
xp
re
ss
io
n
0 3 12 24
0
1
2
3
SNAI2
**
Time Post Biopsy (Hours)R
el
at
iv
e 
no
rm
al
is
ed
 E
xp
re
ss
io
n
Figure 4. Increase in SOX-4/TGF-β and EMT marker expression post biopsy. qPCR was conducted on tumor-derived cDNA samples from
biopsied or non-biopsied mice, and the relative gene expression of TGF-β, SOX-4, EZH2, CDH2, ZEB2, and SNAI2 was normalized to
GAPDH and β-actin and analyzed at 0, 3, 12, and 24 hours post biopsy (n = 5; significance is determined relative to levels at 0 hour post
biopsy by unpaired t test, *P ≤ .05; error bars represent SEM).
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Our experimental findings demonstrate for the first time that in the
setting of malignant breast cancer, performance of a CNB is
associated with a significantly increased incidence of pulmonary
metastases. We also show that an additional impact of CNB includes
creation of a distinctly immunosuppressive and pro-metastatic tumor0.0
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Figure 5. CNB promotes increased frequency of CTCs in peripheral
blood. Blood collected from biopsied and non-biopsied mice at
6 hours, 24 hours, and 10 days post biopsy was analyzed using
real-time qPCR for the relative expression of neomycin (neo)
resistance gene as a measure of the levels of 4T1neo cells in the
peripheral circulation (n= 15; significance determined by unpaired
t test, *P ≤ .05, **P ≤ .01; error bars represent SEM).microenvironment with elevated TGF-β/SOX-4–associated EMT
and significantly higher CTC levels.
In this era of digital mammography when smaller breast cancers are
being detected, presumably in a pre-metastatic state, biologic knowledge
of the potential harms associated with the traditional workup of breast
cancer through the application of a CNB needs to be considered. Further
research to better understand the biologic pathways associated with
surgically induced metastases needs to be conducted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.09.004.
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